These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25343256)

  • 1. TMEM43 mutation p.S358L alters intercalated disc protein expression and reduces conduction velocity in arrhythmogenic right ventricular cardiomyopathy.
    Siragam V; Cui X; Masse S; Ackerley C; Aafaqi S; Strandberg L; Tropak M; Fridman MD; Nanthakumar K; Liu J; Sun Y; Su B; Wang C; Liu X; Yan Y; Mendlowitz A; Hamilton RM
    PLoS One; 2014; 9(10):e109128. PubMed ID: 25343256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMEM43 mutations associated with arrhythmogenic right ventricular cardiomyopathy in non-Newfoundland populations.
    Baskin B; Skinner JR; Sanatani S; Terespolsky D; Krahn AD; Ray PN; Scherer SW; Hamilton RM
    Hum Genet; 2013 Nov; 132(11):1245-52. PubMed ID: 23812740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β.
    Padrón-Barthe L; Villalba-Orero M; Gómez-Salinero JM; Domínguez F; Román M; Larrasa-Alonso J; Ortiz-Sánchez P; Martínez F; López-Olañeta M; Bonzón-Kulichenko E; Vázquez J; Martí-Gómez C; Santiago DJ; Prados B; Giovinazzo G; Gómez-Gaviro MV; Priori S; Garcia-Pavia P; Lara-Pezzi E
    Circulation; 2019 Oct; 140(14):1188-1204. PubMed ID: 31567019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus.
    Milting H; Klauke B; Christensen AH; Müsebeck J; Walhorn V; Grannemann S; Münnich T; Šarić T; Rasmussen TB; Jensen HK; Mogensen J; Baecker C; Romaker E; Laser KT; zu Knyphausen E; Kassner A; Gummert J; Judge DP; Connors S; Hodgkinson K; Young TL; van der Zwaag PA; van Tintelen JP; Anselmetti D
    Eur Heart J; 2015 Apr; 36(14):872-81. PubMed ID: 24598986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5.
    Dominguez F; Zorio E; Jimenez-Jaimez J; Salguero-Bodes R; Zwart R; Gonzalez-Lopez E; Molina P; Bermúdez-Jiménez F; Delgado JF; Braza-Boïls A; Bornstein B; Toquero J; Segovia J; Van Tintelen JP; Lara-Pezzi E; Garcia-Pavia P
    Heart Rhythm; 2020 Jun; 17(6):945-954. PubMed ID: 32062046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The
    Orgil BO; Munkhsaikhan U; Pierre JF; Li N; Xu F; Alberson NR; Johnson JN; Wetzel GT; Boukens BJD; Lu L; Towbin JA; Purevjav E
    Am J Physiol Heart Circ Physiol; 2023 Jun; 324(6):H866-H880. PubMed ID: 37083466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada.
    Haywood AF; Merner ND; Hodgkinson KA; Houston J; Syrris P; Booth V; Connors S; Pantazis A; Quarta G; Elliott P; McKenna W; Young TL
    Eur Heart J; 2013 Apr; 34(13):1002-11. PubMed ID: 23161701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise and arrhythmic risk in TMEM43 p.S358L arrhythmogenic right ventricular cardiomyopathy.
    Paulin FL; Hodgkinson KA; MacLaughlan S; Stuckless SN; Templeton C; Shah S; Bremner H; Roberts JD; Young TL; Parfrey PS; Connors SP
    Heart Rhythm; 2020 Jul; 17(7):1159-1166. PubMed ID: 32120009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Expression of
    Zink M; Seewald A; Rohrbach M; Brodehl A; Liedtke D; Williams T; Childs SJ; Gerull B
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation analysis and evaluation of the cardiac localization of TMEM43 in arrhythmogenic right ventricular cardiomyopathy.
    Christensen AH; Andersen CB; Tybjaerg-Hansen A; Haunso S; Svendsen JH
    Clin Genet; 2011 Sep; 80(3):256-64. PubMed ID: 21214875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant accumulation of TMEM43 accompanied by perturbed transmural gene expression in arrhythmogenic cardiomyopathy.
    Shinomiya H; Kato H; Kuramoto Y; Watanabe N; Tsuruda T; Arimura T; Miyashita Y; Miyasaka Y; Mashimo T; Takuwa A; Motooka D; Okuzaki D; Matsuoka K; Tsukamoto O; Hakui H; Yamada N; Lee JK; Kioka H; Kitakaze M; Takashima S; Sakata Y; Asano Y
    FASEB J; 2021 Nov; 35(11):e21994. PubMed ID: 34674311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy.
    Li D; Liu Y; Maruyama M; Zhu W; Chen H; Zhang W; Reuter S; Lin SF; Haneline LS; Field LJ; Chen PS; Shou W
    Hum Mol Genet; 2011 Dec; 20(23):4582-96. PubMed ID: 21880664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene.
    Merner ND; Hodgkinson KA; Haywood AF; Connors S; French VM; Drenckhahn JD; Kupprion C; Ramadanova K; Thierfelder L; McKenna W; Gallagher B; Morris-Larkin L; Bassett AS; Parfrey PS; Young TL
    Am J Hum Genet; 2008 Apr; 82(4):809-21. PubMed ID: 18313022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-Exome Sequencing Identified a De Novo Mutation of
    Liu L; Chen C; Li Y; Yu R
    Biomed Res Int; 2019; 2019():9103860. PubMed ID: 31275992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional effects of the TMEM43 Ser358Leu mutation in the pathogenesis of arrhythmogenic right ventricular cardiomyopathy.
    Rajkumar R; Sembrat JC; McDonough B; Seidman CE; Ahmad F
    BMC Med Genet; 2012 Mar; 13():21. PubMed ID: 22458570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connexin expression patterns in arrhythmogenic right ventricular cardiomyopathy.
    Paul M; Wichter T; Gerss J; Arps V; Schulze-Bahr E; Robenek H; Breithardt G; Weissen-Plenz G
    Am J Cardiol; 2013 May; 111(10):1488-95. PubMed ID: 23465095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease).
    Kaplan SR; Gard JJ; Protonotarios N; Tsatsopoulou A; Spiliopoulou C; Anastasakis A; Squarcioni CP; McKenna WJ; Thiene G; Basso C; Brousse N; Fontaine G; Saffitz JE
    Heart Rhythm; 2004 May; 1(1):3-11. PubMed ID: 15851108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy.
    Asimaki A; Syrris P; Wichter T; Matthias P; Saffitz JE; McKenna WJ
    Am J Hum Genet; 2007 Nov; 81(5):964-73. PubMed ID: 17924338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychological Distress and Quality of Life in Participants Undergoing Genetic Testing for Arrhythmogenic Right Ventricular Cardiomyopathy Caused by TMEM43 p.S358L: Is It Time to Offer Population-Based Genetic Screening?
    Brothers C; Etchegary H; Curtis F; Simmonds C; Houston J; Young TL; Pullman D; Mariathas HH; Connors S; Hodgkinson K
    Public Health Genomics; 2021; 24(5-6):253-260. PubMed ID: 34500452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.